ReviewHuman
Relaxin agonists under preclinical and early clinical investigation for the treatment of heart failure
Expert opinion on investigational drugs, 2024 Dec. Ajay A, Biju P, Ajay H and 3 others.
Study type
Review
Subjects
Human participants (PubMed MeSH: Humans)
Journal
Expert opinion on investigational drugs
Published
2024 Dec
PubMed
Where PepCue cites this
This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.
Indexed under
MeSH terms assigned by the National Library of Medicine.
HumansHeart FailureRelaxinAnimalsAcute DiseaseBiomarkersDrug Development
Other papers on B7-33
Randomized controlled trial · 2025
End-organ protective effect of serelaxin in patients hospitalized for heart failure: Results of the biomarker substudy of Relaxin in Acute Heart Failure-2 (RELAX-AHF-2)
Journal article · 2023The single-chain relaxin mimetic, B7-33, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy
Journal article · 2016A single-chain derivative of the relaxin hormone is a functionally selective agonist of the G protein-coupled receptor, RXFP1
PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.
Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page